The article “Forecasting Seizures” in the May/June issue incorrectly stated that the trial that “allowed [Neuropace] to enroll 220 people” is closed. The feasibility trial ended over a year ago and is closed; but the current pivotal trial is still open for enrollment. (At press time, the National Institutes of Health Web site clinicaltrials.gov had not been updated.)
The RNS System is a novel therapeutic device that uses advanced technology to detect and suppress abnormal electrical activity in the brain before seizure symptoms occur. The new device builds upon established neurostimulation technology that is FDA approved to treat Parkinson's disease and essential tremor.
The RNS System Pivotal Clinical Investigation aims to assess the safety and effectiveness of RNS as an add-on therapy for reducing the frequency of seizures. Eligible participants should be 18 to 70 years of age with partial onset seizures that are refractory to two or more antiepileptic medications. Visit seizurestudy.com or call 866-903-3678 for more information about enrollment for this trial.